Tscan therapeutics appoints r. keith woods to its board of directors, bringing expertise in commercialization and global operations

Waltham, mass., dec. 07, 2023 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the appointment of r. keith woods to its board of directors. mr. woods has over 30 years of life science experience, with expertise in commercialization, sales, global operations, supply chain and business strategy.
TCRX Ratings Summary
TCRX Quant Ranking